Combination of clofarabine, etoposide, and cyclophosphamide in adult relapsed/refractory acute lymphoblastic leukemia: a phase 1/2 dose-escalation study by the Japan Adult Leukemia Study Group
- 23 November 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in International Journal of Hematology
- Vol. 113 (3), 395-403
- https://doi.org/10.1007/s12185-020-03032-3
Abstract
This phase 1/2 study aimed to identify the maximum tolerated dose, the recommended phase 2 dose (RP2D), and efficacy of the clofarabine, etoposide, and cyclophosphamide combination regimen in adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL). Patients aged ≥ 15 years with relapsed/refractory ALL were enrolled. Escalating doses of clofarabine (20–30 mg/m2/day × 5 days), etoposide (50–100 mg/m2/day × 5 days), and cyclophosphamide (200–440 mg/m2/day × 5 days) were administered. Dose-limiting toxicity was defined as Grade 3 or more non-hematological toxicities and others. A total of 18 patients (B-ALL; n = 13, T-ALL; n = 5) were recruited in phase 1; however, the protocol was amended to close study without proceeding to phase 2. Three patients were enrolled in cohort 1, three in cohort 2, six in cohort 3, and six in cohort 4. The RP2D of clofarabine, etoposide, and cyclophosphamide was 30, 100, and 440 mg/m2 daily, respectively. Complete remission (CR) was achieved in four patients (22%) and CR without platelet recovery in four patients (22%), with an overall response rate of 44%. The RP2D of the combination therapy was successfully determined in this study.Keywords
Funding Information
- Japan Agency for Medical Research and Development (Grant Number JP19ck0106331)
This publication has 23 references indexed in Scilit:
- Outcome after first relapse in adult patients with Philadelphia chromosome‐negative acute lymphoblastic leukaemiaBritish Journal of Haematology, 2013
- Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemiaBlood, 2011
- A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemiaLeukemia, 2009
- Pediatric-Inspired Therapy in Adults With Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia: The GRAALL-2003 StudyJournal of Clinical Oncology, 2009
- Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st centuryBlood, 2009
- Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 studyBlood, 2006
- FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemiaAnnals of Hematology, 2005
- Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemiaBlood, 2004
- Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemiaBlood, 2003